Novartis AG (NYSE:NVS – Free Report) – Analysts at Erste Group Bank lowered their FY2026 earnings per share estimates for Novartis in a research report issued to clients and investors on Wednesday, July 15th. Erste Group Bank analyst H. Engel now expects that the company will post earnings per share of $8.90 for the year, down from their previous estimate of $9.01. The consensus estimate for Novartis’ current full-year earnings is $8.75 per share.
Novartis (NYSE:NVS – Get Free Report) last posted its earnings results on Monday, April 27th. The company reported $1.99 earnings per share for the quarter, missing the consensus estimate of $2.11 by ($0.12). The firm had revenue of $13.52 billion during the quarter, compared to analysts’ expectations of $13.44 billion. Novartis had a net margin of 24.87% and a return on equity of 38.82%. The firm’s revenue for the quarter was down .9% on a year-over-year basis. During the same period in the previous year, the firm posted $2.28 earnings per share.
Novartis Trading Down 2.8%
NYSE:NVS opened at $149.48 on Monday. The stock’s 50 day moving average price is $151.50 and its 200 day moving average price is $151.77. The company has a market capitalization of $285.23 billion, a PE ratio of 21.42, a P/E/G ratio of 2.65 and a beta of 0.45. The company has a quick ratio of 0.65, a current ratio of 0.85 and a debt-to-equity ratio of 0.96. Novartis has a 52-week low of $112.34 and a 52-week high of $170.46.
Hedge Funds Weigh In On Novartis
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Brighton Jones LLC grew its stake in shares of Novartis by 76.5% in the 4th quarter. Brighton Jones LLC now owns 6,153 shares of the company’s stock valued at $599,000 after purchasing an additional 2,666 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of Novartis by 102.8% during the first quarter. AQR Capital Management LLC now owns 22,573 shares of the company’s stock worth $2,516,000 after purchasing an additional 11,444 shares during the last quarter. Empowered Funds LLC purchased a new stake in shares of Novartis during the first quarter worth approximately $1,764,000. Sivia Capital Partners LLC lifted its holdings in shares of Novartis by 48.0% during the second quarter. Sivia Capital Partners LLC now owns 7,959 shares of the company’s stock worth $963,000 after purchasing an additional 2,581 shares during the period. Finally, Schnieders Capital Management LLC. acquired a new stake in shares of Novartis during the second quarter worth $202,000. Hedge funds and other institutional investors own 13.12% of the company’s stock.
About Novartis
Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.
The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.
Further Reading
- Five stocks we like better than Novartis
- The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
- Is Domino’s Stock Serving Up a Buying Opportunity?
- A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free
- Why Gold Miners Could Be the Market’s Biggest Comeback Story
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.
